1. The company’s general administrative expenses rose from $1.3 million in the second quarter of 2013 to $1.8 million. Research and development costs increased from $1.2 million in the second quarter of 2013 to $2.8 million.
2. The company formed an irritable bowel syndrome clinical advisory board in the spring of this year. Synthetics Biologics has filed new patent applications for the C-IBS program.
3. The company has also announced plans to file INDs and initiate clinical trials this year for its C. difficile and C-IBS programs.
More articles on gastroenterology:
3 Southern GI practices partner with LifeLinc Anesthesia
FDA approves colonoscopy alternative Cologuard: 4 things to know
Best ideas for entrepreneurial gastroenterologists: Public presence, ASC ownership & more
